Novo Nordisk A/S revealed details from a key study backing the use of Wegovy, its blockbuster weight-loss drug, to cut heart attacks and deaths in obesity patients with a history of cardiovascular ...

Novo Nordisk shares rose 3.3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not ...

Novo Nordisk's NVO, +1.16% popular weight-loss drug Wegovy significantly cut the risk of heart attack, stroke or death due to cardiovascular disease in people who do not have diabetes, according to...

Novo Nordisk on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical...

The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.

Novo has struggled to keep up with booming demand for its weight loss drug and said it could be years until it or its rivals are able to satisfy the growing market.

Novo Nordisk NVO, -1.36% said Friday that it will invest more than $6 billion to expand manufacturing facilities in Kalundborg, Denmark, where the company produces GLP-1 drugs such as Wegovy as wel...

Novo Nordisk wants to buy more companies with drugs in early- to mid-stages of development through "bolt-on" deals of up to a few billion dollars, CEO Lars Fruergaard Jorgensen told Reuters on Friday.

Europe's largest pharma company, Novo Nordisk (NYSE:NVO), has unveiled plans for a significant investment of more than $6 billion to cater to the increasing demand for its Wegovy weight-loss treatm...

Novo Nordisk said on Friday it will invest more than 42 billion Danish crowns ($6 billion) from 2023 onwards to expand its manufacturing facilities in Denmark for the current and future product por...

Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.

Danish drugmaker Novo Nordisk said on Tuesday it will present new cardiometabolic disease data, including results from its SELECT trial, at the annual American Heart Association Scientific Sessions...

Two analysts separately raised their price targets on the shares. This provides even more bullish momentum for the Wegovy and Ozempic maker's stock.

An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events.

Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next week. It was the “stunning” numbers from the prev...